Volatile Organic Compounds Sample Clauses

Volatile Organic Compounds. Analyses for volatile organic compounds (VOCs) were performed on all the soil and groundwater samples with the exception of surface soils. In addition, 17 soil vapor samples from 13 vapor wellx xxxated throughout the mound and panhandle were analyzed for selected organic gases and vapors. Consequently, VOC analyses performed on non-refuse fill area media included 10 soil and 3 shallow groundwater samples; no VOCs were detected in any of these samples. The panhandle sampling media included 3 soil vapor samples. 3 subsurface soil samples, and 4 groundwater samples (one shallow and three deeper, which includes one repeat sample from one of the deeper wellx). Xoil vapor sampling in the panhandle area indicated the general absence of volatiles, with detected compounds being the same as those detected in the trip blanks. Similarly, no VOCs were detected in the soil samples. The shallow groundwater sample yielded a few volatiles (97 ppb toluene, 48 ppb ethylbenzene, and 80 ppb total xylenes); one of the deeper groundwater samples (P-1B) yielded 7 ppb 1,1,1-trichloroethane and 10 ppb trichloroethene. Repeat sampling of well P-1B failed to detect these contaminants. The refuse mound area had a total of 14 soil vapor samples, 7 subsurface soil samples, and 4 groundwater samples (2 shallow and 2 deeper). The soil vapor sampling indicated the presence of a number of landfill gases. However, vinyl chloride was not detected. No VOCs were detected in the soil samples. The shallow groundwater, like that of the panhandle, yielded detectable levels of a few volatile compounds (6-40 ppb toluene, 16-24 ppb ethylbenzene, and 12 ppb total xylenes). Neither of the two deeper mound groundwater samples had detectable VOCs. Off-Site VOC sampling consisted of three groundwater well samples south of the site (two deeper samples from UCP-1 and one from shallow sample from UCP-2) and one shallow well sample northeast of the site (MV-3). The deeper well sample revealed trace levels of 1,1,1-trichlorocthane (6 ppb) and trichloroethene (7 ppb) when first sampled; these findings were not substantiated by repeat sampling. The shallow well samples revealed no VOCs. The soil vapor sampling indicates the presence of a variety of volatile landfill gases present in the mound area of the site at relatively low concentrations (less than 1.0 ppm). McLaren's groundwater sampling results are consistent with prior sampling performed by Levixx-Xxxxxx (0089 a,c) in that no VOCs were detected in the non-...
AutoNDA by SimpleDocs
Volatile Organic Compounds. EPA Method TO -14 Summa Canister None None 1 14 days to analysis EPA Method TO -15 Summa Canister None None 1 14 days to analysis EPA Method TO -17 Adsorbent Tubes chill to 4°C. None 1 30 days to analysis Air and Soil Gas - Organics, Volatile Organic Compounds EPA Method 504.1 40-xX xxxxx VOA vial chill to 4°C. sodium thiosulfate 3 14 days to analysis EPA Method 524.2 40-mL xxxxx xxxxx VOA vial chill to 4°C. HCl to pH ≤ 2 (residual chlorine present add ascorbic acid) 3 14 days to analysis EPA Method 8260B 40-xX xxxxx VOA vial chill to 4°C. HCl to pH ≤ 2 3 14 days to analysis EPA Method CaDPH 40-mL xxxxx xxxxx VOA vial chill to 4°C. None; (residual chlorine present 3 14 days to analysis 1,2,3-Trichloropropane Method-VOA add ascorbic acid)
Volatile Organic Compounds. Product offerings must be in compliance with stringent emission levels for volatile organic compounds in accordance with ANSI/BIFMA e3-2014 Furniture Sustainability Standard, Sections 7.6.1 and 7.6.2 as such standard may be updated or superseded from time to time, using either the concentration modeling approach or the emissions factor approach.

Related to Volatile Organic Compounds

  • Combination Products If a LICENSED PRODUCT is sold to any third party in combination with other products, devices, components or materials that are capable of being sold separately and are not subject to royalties hereunder (“OTHER PRODUCTS,” with the combination of products being referred to as “COMBINATION PRODUCTS” and the Other Product and Licensed Product in such Combination Product being referred to as the “COMPONENTS”), the NET SALES of such LICENSED PRODUCT included in such COMBINATION PRODUCT shall be calculated by multiplying the NET SALES of the COMBINATION PRODUCT by the fraction A/(A+B), where A is the average NET SALES price of such LICENSED PRODUCT in the relevant country, as sold separately, and B is the total average NET SALES price of all OTHER PRODUCTS in the COMBINATION PRODUCT in the relevant country, as sold separately. If, in any country, any COMPONENT is not sold separately, NET SALES for royalty determination shall be determined by the formula [C / (C+D)], where C is the aggregate average fully absorbed cost of the Licensed Product components during the prior Royalty Period and D is the aggregate average fully absorbed cost of the other essential functional components during the prior Royalty Period, with such costs being determined in accordance with generally accepted accounting principles. To the extent that any SUBLICENSE INCOME relates to a COMBINATION PRODUCT or is otherwise calculated based on the value of one or more licenses or intellectual property rights held by the COMPANY, an AFFILIATE or SUBLICENSEE, COMPANY shall determine in good faith and report to THE PARTIES the share of such payments reasonably attributable to COMPANY’s or such AFFILIATE’s sublicense of the rights granted hereunder, based upon their relative importance and proprietary protection, which portion shall be the SUBLICENSE INCOME. THE PARTIES shall have the right to dispute such sharing determination in accordance with the dispute provisions of the AGREEMENT.

  • Combination Product The term “

  • Formation; Composition Within […***…] days after the Effective Date, the Parties shall establish a committee to oversee Development of Licensed Product(s) in the Territory in accordance with the Development Plan(s) for the same and to coordinate the Development activities of the Parties, and review and discuss the Development and Manufacture of Licensed Compound and Licensed Products (the “JDC”). Each Party shall initially appoint three (3) representatives to the JDC, with each representative having knowledge and expertise in the development of compounds and products similar to the Licensed Products and having sufficient seniority within the applicable Party to make decisions arising within the scope of the JDC’s responsibilities. The JDC may change its size from time to time if agreed by consensus among its members, provided that the JDC shall consist at all times of an equal number of representatives of each of Galapagos and Gilead. Each Party may replace its JDC representatives at any time upon written notice to the other Party. The JDC may invite non-members to participate in the discussions and meetings of the JDC, provided that such participants shall have no voting authority at the JDC. The JDC shall have a chairperson, who shall serve for a term of one (1) year, and who shall be selected alternately, on an annual basis, by Galapagos or Gilead. The initial chairperson shall be selected by […***…]. The role of the chairperson shall be to convene and preside at meetings of the JDC and to ensure the preparation of minutes, but the chairperson shall have no additional powers or rights beyond those held by the other JDC representatives.

  • Licensed Product “Licensed Product” shall mean any article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights. For clarity, a “Licensed Product” shall not include other product or material that (a) is used in combination with Licensed Product, and (b) does not constitute an article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights.

  • Competing Products The provisions of Section 21 are set forth on attached Exhibit H and are incorporated in this Section 21 by this reference.

  • Clinical Data The descriptions of the results of any studies and tests conducted by or on behalf of, or sponsored by, the Company or its subsidiaries, or in which the Company has participated, that are described in the Disclosure Package and the Prospectus, or the results of which are referred to in the Disclosure Package and the Prospectus do not contain any misstatement of material fact or omit to state a material fact necessary to make such statements not misleading. The Company has no knowledge of any studies or tests not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Disclosure Package or Prospectus.

  • Change in Board Composition During any period of two consecutive years, individuals who constitute the Company’s Board of Directors at the beginning of the two-year period cease for any reason to constitute at least a majority of the Company’s Board of Directors; provided, however, that for purposes of this clause (iii), each director who is first elected by the board (or first nominated by the board for election by the stockholders) by a vote of at least two-thirds (2/3) of the directors who were directors at the beginning of the two-year period shall be deemed to have also been a director at the beginning of such period; or

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • Product ACCEPTANCE Unless otherwise provided by mutual agreement of the Authorized User and the Contractor, Authorized User(s) shall have thirty (30) days from the date of delivery to accept hardware products and sixty (60) days from the date of delivery to accept all other Product. Where the Contractor is responsible for installation, acceptance shall be from completion of installation. Failure to provide notice of acceptance or rejection or a deficiency statement to the Contractor by the end of the period provided for under this clause constitutes acceptance by the Authorized User(s) as of the expiration of that period. The License Term shall be extended by the time periods allowed for trial use, testing and acceptance unless the Commissioner or Authorized User agrees to accept the Product at completion of trial use. Unless otherwise provided by mutual agreement of the Authorized User and the Contractor, Authorized User shall have the option to run testing on the Product prior to acceptance, such tests and data sets to be specified by User. Where using its own data or tests, Authorized User must have the tests or representative set of data available upon delivery. This demonstration will take the form of a documented installation test, capable of observation by the Authorized User, and shall be made part of the Contractor’s standard documentation. The test data shall remain accessible to the Authorized User after completion of the test. In the event that the documented installation test cannot be completed successfully within the specified acceptance period, and the Contractor or Product is responsible for the delay, Authorized User shall have the option to cancel the order in whole or in part, or to extend the testing period for an additional thirty (30) day increment. Authorized User shall notify Contractor of acceptance upon successful completion of the documented installation test. Such cancellation shall not give rise to any cause of action against the Authorized User for damages, loss of profits, expenses, or other remuneration of any kind. If the Authorized User elects to provide a deficiency statement specifying how the Product fails to meet the specifications within the testing period, Contractor shall have thirty (30) days to correct the deficiency, and the Authorized User shall have an additional sixty (60) days to evaluate the Product as provided herein. If the Product does not meet the specifications at the end of the extended testing period, Authorized User, upon prior written notice to Contractor, may then reject the Product and return all defective Product to Contractor, and Contractor shall refund any monies paid by the Authorized User to Contractor therefor. Costs and liabilities associated with a failure of the Product to perform in accordance with the functionality tests or product specifications during the acceptance period shall be borne fully by Contractor to the extent that said costs or liabilities shall not have been caused by negligent or willful acts or omissions of the Authorized User’s agents or employees. Said costs shall be limited to the amounts set forth in the Limitation of Liability Clause for any liability for costs incurred at the direction or recommendation of Contractor.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!